Language:
  
[Sign in] [Register]   

EIAab logo

Index > Protein center > IGF1R(Gene name) > Human
  • Add your favorite
  • IGF1R (Gene name),
  • Insulin-like growth factor 1 receptor (Protein name ),  IGF1R_HUMAN from NCBI database.
  • top
  • Come back to page head.
  • |
  • General Annotation
  • |
  • Antigen Annotation
  • |
  • 3D
  • |
  • Predicted Eptitope
  • |
  • Vaild Sequence
  • |
  • Related Databases
  • |
  • Feedback
  • Gene name:
    IGF1R;
    Protein name:
    Insulin-like growth factor 1 receptor;
    Alternative:
    Insulin-like growth factor I receptor(IGF-I receptor);
    CD:
    CD221;
    Organism:
    Human (Homo sapiens). 
    General Annotation
    Sub Unit:
    Tetramer of 2 alpha and 2 beta chains linked by disulfide bonds. The alpha chains contribute to the formation of the ligand-binding domain, while the beta chain carries the kinase domain. Interacts with PIK3R1 and with the PTB/PID domains of IRS1 and SHC1 in vitro when autophosphorylated on tyrosine residues. Forms a hybrid receptor with INSR, the hybrid is a tetramer consisting of 1 alpha chain and 1 beta chain of INSR and 1 alpha chain and 1 beta chain of IGF1R. Interacts with ARRB1 and ARRB2. Interacts with GRB10. Interacts with GNB2L1/RACK1.
    Function:
    This receptor binds insulin-like growth factor 1 (IGF1) with a high affinity and IGF2 with a lower affinity. It has a tyrosine-protein kinase activity, which is necessary for the activation of the IGF1-stimulated downstream signaling cascade. When present in a hybrid receptor with INSR, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.
    Subcellular Location:
    Membrane Single-pass type I membrane protein
    Protein Attributes:
    Sequence length:
    1367
    Sequence:
    50:
    MKSGSGGGSP | TSLWGLLFLS | AALSLWPTSG | EICGPGIDIR | NDYQQLKRLE | 
    100:
    NCTVIEGYLH | ILLISKAEDY | RSYRFPKLTV | ITEYLLLFRV | AGLESLGDLF | 
    150:
    PNLTVIRGWK | LFYNYALVIF | EMTNLKDIGL | YNLRNITRGA | IRIEKNADLC | 
    200:
    YLSTVDWSLI | LDAVSNNYIV | GNKPPKECGD | LCPGTMEEKP | MCEKTTINNE | 
    250:
    YNYRCWTTNR | CQKMCPSTCG | KRACTENNEC | CHPECLGSCS | APDNDTACVA | 
    300:
    CRHYYYAGVC | VPACPPNTYR | FEGWRCVDRD | FCANILSAES | SDSEGFVIHD | 
    350:
    GECMQECPSG | FIRNGSQSMY | CIPCEGPCPK | VCEEEKKTKT | IDSVTSAQML | 
    400:
    QGCTIFKGNL | LINIRRGNNI | ASELENFMGL | IEVVTGYVKI | RHSHALVSLS | 
    450:
    FLKNLRLILG | EEQLEGNYSF | YVLDNQNLQQ | LWDWDHRNLT | IKAGKMYFAF | 
    500:
    NPKLCVSEIY | RMEEVTGTKG | RQSKGDINTR | NNGERASCES | DVLHFTSTTT | 
    550:
    SKNRIIITWH | RYRPPDYRDL | ISFTVYYKEA | PFKNVTEYDG | QDACGSNSWN | 
    600:
    MVDVDLPPNK | DVEPGILLHG | LKPWTQYAVY | VKAVTLTMVE | NDHIRGAKSE | 
    650:
    ILYIRTNASV | PSIPLDVLSA | SNSSSQLIVK | WNPPSLPNGN | LSYYIVRWQR | 
    700:
    QPQDGYLYRH | NYCSKDKIPI | RKYADGTIDI | EEVTENPKTE | VCGGEKGPCC | 
    750:
    ACPKTEAEKQ | AEKEEAEYRK | VFENFLHNSI | FVPRPERKRR | DVMQVANTTM | 
    800:
    SSRSRNTTAA | DTYNITDPEE | LETEYPFFES | RVDNKERTVI | SNLRPFTLYR | 
    850:
    IDIHSCNHEA | EKLGCSASNF | VFARTMPAEG | ADDIPGPVTW | EPRPENSIFL | 
    900:
    KWPEPENPNG | LILMYEIKYG | SQVEDQRECV | SRQEYRKYGG | AKLNRLNPGN | 
    950:
    YTARIQATSL | SGNGSWTDPV | FFYVQAKTGY | ENFIHLIIAL | PVAVLLIVGG | 
    1000:
    LVIMLYVFHR | KRNNSRLGNG | VLYASVNPEY | FSAADVYVPD | EWEVAREKIT | 
    1050:
    MSRELGQGSF | GMVYEGVAKG | VVKDEPETRV | AIKTVNEAAS | MRERIEFLNE | 
    1100:
    ASVMKEFNCH | HVVRLLGVVS | QGQPTLVIME | LMTRGDLKSY | LRSLRPEMEN | 
    1150:
    NPVLAPPSLS | KMIQMAGEIA | DGMAYLNANK | FVHRDLAARN | CMVAEDFTVK | 
    1200:
    IGDFGMTRDI | YETDYYRKGG | KGLLPVRWMS | PESLKDGVFT | TYSDVWSFGV | 
    1250:
    VLWEIATLAE | QPYQGLSNEQ | VLRFVMEGGL | LDKPDNCPDM | LFELMRMCWQ | 
    1300:
    YNPKMRPSFL | EIISSIKEEM | EPGFREVSFY | YSEENKLPEP | EELDLEPENM | 
    1350:
    ESVPLDPSAS | SSSLPLPDRH | SGHKAENGPG | PGVLVLRASF | DERQPYAHMN | 
    1367:
    GGRKNERALP | LPQSSTC
    3D Structure:
    N/A
    Predicted Eptitope:
    Please Sign in.
    EIAab Sequence  Vaild Sequence:
    Please Sign in.
    Related Databases
    UniGene:
    KEGG:
    SMR:
    String:
    Pfam:
    MIM:
    Uniprot:
     
    FOR
    ELISA Kit for Human Insulin-like growth factor 1 receptor
    Cat.:
    E1200h
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    ELISA Kit for Human Insulin-like growth factor 1 receptor
    Cat.:
    E1200p
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    ELISA Kit for Human Insulin-like growth factor 1 receptor
    Cat.:
    E1200b
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    ELISA Kit for Human Insulin-like growth factor 1 receptor
    Cat.:
    E1200r
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    ELISA Kit for Human Insulin-like growth factor 1 receptor
    Cat.:
    E1200m
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    CLIA Kit for Human Insulin-like growth factor 1 receptor
    MSDS:
    Please sign in first.
    CLIA Kit for Human Insulin-like growth factor 1 receptor
    Cat.:
    U1200p
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    CLIA Kit for Human Insulin-like growth factor 1 receptor
    Cat.:
    U1200m
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    CLIA Kit for Human Insulin-like growth factor 1 receptor
    Cat.:
    U1200h
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    CLIA Kit for Human Insulin-like growth factor 1 receptor
    Cat.:
    U1200r
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Polyclonal Antibody for Human Insulin-like growth factor 1 receptor
    Cat.:
    P1200Rb-h
    Price:
    Please sign in first.
    Packing:
    40ug/0.2ml
    Polyclonal Antibody for Human Insulin-like growth factor 1 receptor
    Cat.:
    P1200Rb-r
    Price:
    Please sign in first.
    Packing:
    40ug/0.2ml
    Polyclonal Antibody for Human Insulin-like growth factor 1 receptor
    Cat.:
    P1200Rb-m
    Price:
    Please sign in first.
    Packing:
    40ug/0.2ml
    Polyclonal Antibody for Human Insulin-like growth factor 1 receptor
    Polyclonal Antibody for Human Insulin-like growth factor 1 receptor
    Monoclonal Antibody for Human Insulin-like growth factor 1 receptor
    Monoclonal Antibody for Human Insulin-like growth factor 1 receptor
    Monoclonal Antibody for Human Insulin-like growth factor 1 receptor
    Monoclonal Antibody for Human Insulin-like growth factor 1 receptor
    Monoclonal Antibody for Human Insulin-like growth factor 1 receptor
    Protein for Human Insulin-like growth factor 1 receptor
    Protein for Human Insulin-like growth factor 1 receptor
    Protein for Human Insulin-like growth factor 1 receptor
    Protein for Human Insulin-like growth factor 1 receptor
    Protein for Human Insulin-like growth factor 1 receptor

    R&D Technical Data
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Precision
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Recovery
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Linearity
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    References
    1. 1.
      "Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity."
      Ullrich A. , Gray A. , Tam A.W. , Yang-Feng T. , Tsubokawa M. , Collins C. , Henzel W. , Bon T.L. , Kathuria S. , Chen E. , Jacobs S. , Francke U. , Ramachandran J. , Fujita-Yamaguchi Y.
      EMBO J.5:2503-2512(1986) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA];PROTEIN SEQUENCE OF 31-56; 446-453; 503-524; 561-579; 668-672 AND 721-729
      tissue: Placenta.
    2. 2.
      "Insulin-like growth factor I receptor gene structure."
      Abbot A.M. , Bueno R. , Pedrini M.T. , Murray J.M. , Smith R.J.
      J. Biol. Chem.267:10759-10763(1992) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]
    3. 3.
      Nagase T. , Kikuno R.F. , Yamakawa H. , Ohara O.
      Submitted (2008-02) to the EMBL/GenBank/DDBJ databases
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]
      tissue: Fetal brain.
    4. 4.
      NIEHS SNPs program
      Submitted (2003-06) to the EMBL/GenBank/DDBJ databases
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA];VARIANTS MET-388 AND HIS-605
    5. 6.
      "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."
      The MGC Project Team
      Genome Res.14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]
    6. 7.
      "Analysis of the human type I insulin-like growth factor receptor promoter region."
      Cooke D.W. , Bankert L.A. , Roberts C.T. Jr. , Leroith D. , Casella S.J.
      Biochem. Biophys. Res. Commun.177:1113-1120(1991) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-31
    7. 8.
      "Characterization of human placental insulin-like growth factor-I/insulin hybrid receptors by protein microsequencing and purification."
      Kasuya J. , Paz I.B. , Maddux B.A. , Goldfine I.D. , Hefta S.A. , Fujita-Yamaguchi Y.
      Biochemistry32:13531-13536(1993) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: PROTEIN SEQUENCE OF 31-45 AND 741-750;FUNCTION;FORMATION OF A HYBRID RECEPTOR WITH INSR
      tissue: Placenta.
    8. 9.
      "A survey of protein tyrosine kinase mRNAs expressed in normal human melanocytes."
      Lee S.-T. , Strunk K.M. , Spritz R.A.
      Oncogene8:3403-3410(1993) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 1137-1193;TISSUE SPECIFICITY
      tissue: Melanocyte.
    9. 10.
      "Interaction of the alpha beta dimers of the insulin-like growth factor I receptor is required for receptor autophosphorylation."
      Tollefsen S.E. , Stoszek R.M. , Thompson K.
      Biochemistry30:48-54(1991) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: FUNCTION;SUBUNIT;AUTOPHOSPHORYLATION
    10. 11.
      "Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity."
      Soos M.A. , Field C.E. , Siddle K.
      Biochem. J.290:419-426(1993) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: FUNCTION;FORMATION OF A HYBRID RECEPTOR WITH INSR
    11. 12.
      "Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-I) receptor. Characterization of kinase-deficient IGF-I receptors and the action of an IGF-I-mimetic antibody (alpha IR-3)."
      Kato H. , Faria T.N. , Stannard B. , Roberts C.T. Jr. , LeRoith D.
      J. Biol. Chem.268:2655-2661(1993) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: FUNCTION;CATALYTIC ACTIVITY;AUTOPHOSPHORYLATION
    12. 13.
      "Non-SH2 domains within insulin receptor substrate-1 and SHC mediate their phosphotyrosine-dependent interaction with the NPEY motif of the insulin-like growth factor I receptor."
      Craparo A. , O'Neill T.J. , Gustafson T.A.
      J. Biol. Chem.270:15639-15643(1995) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: INTERACTION WITH IRS1; SHC1 AND PIK3R1;MUTAGENESIS OF TYR-980 AND LYS-1033;PHOSPHORYLATION AT TYR-980
    13. 14.
      "Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting."
      Bailyes E.M. , Nave B.T. , Soos M.A. , Orr S.R. , Hayward A.C. , Siddle K.
      Biochem. J.327:209-215(1997) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: FORMATION OF A HYBRID RECEPTOR WITH INSR;TISSUE SPECIFICITY
    14. 15.
      "14-3-3 proteins interact with the insulin-like growth factor receptor but not the insulin receptor."
      Furlanetto R.W. , Dey B.R. , Lopaczynski W. , Nissley S.P.
      Biochem. J.327:765-771(1997) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: INTERACTION WITH 14-3-3 PROTEINS
    15. 16.
      "Distribution of insulin/insulin-like growth factor-I hybrid receptors in human tissues."
      Federici M. , Porzio O. , Zucaro L. , Fusco A. , Borboni P. , Lauro D. , Sesti G.
      Mol. Cell. Endocrinol.129:121-126(1997) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: FORMATION OF A HYBRID RECEPTOR WITH INSR;TISSUE SPECIFICITY
    16. 17.
      "Interaction of human suppressor of cytokine signaling (SOCS)-2 with the insulin-like growth factor-I receptor."
      Dey B.R. , Spence S.L. , Nissley P. , Furlanetto R.W.
      J. Biol. Chem.273:24095-24101(1998) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: INTERACTION WITH SOCS1 AND SOCS2
    17. 18.
      "beta-arrestins regulate mitogenic signaling and clathrin-mediated endocytosis of the insulin-like growth factor I receptor."
      Lin F.-T. , Daaka Y. , Lefkowitz R.J.
      J. Biol. Chem.273:31640-31643(1998) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: INTERACTION WITH ARRB1 AND ARRB2
    18. 19.
      "The IGF-I receptor in cancer research."
      Baserga R.
      Exp. Cell Res.253:1-6(1999) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: FUNCTION IN CANCER
    19. 20.
      "Grb10, a positive, stimulatory signaling adapter in platelet-derived growth factor BB-, insulin-like growth factor I-, and insulin-mediated mitogenesis."
      Wang J. , Dai H. , Yousaf N. , Moussaif M. , Deng Y. , Boufelliga A. , Swamy O.R. , Leone M.E. , Riedel H.
      Mol. Cell. Biol.19:6217-6228(1999) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: INTERACTION WITH GRB10;MUTAGENESIS OF TYR-980; TYR-1280; TYR-1281 AND TYR-1346
    20. 21.
      "Suppressor of cytokine signaling (SOCS)-3 protein interacts with the insulin-like growth factor-I receptor."
      Dey B.R. , Furlanetto R.W. , Nissley P.
      Biochem. Biophys. Res. Commun.278:38-43(2000) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: INTERACTION WITH SOCS3
    21. 22.
      "Autophosphorylation of the insulin-like growth factor I receptor cytoplasmic domain."
      Lopaczynski W. , Terry C. , Nissley P.
      Biochem. Biophys. Res. Commun.279:955-960(2000) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: AUTOPHOSPHORYLATION
    22. 23.
      "Mechanism of STAT3 activation by insulin-like growth factor I receptor."
      Zong C.S. , Chan J. , Levy D.E. , Horvath C. , Sadowski H.B. , Wang L.H.
      J. Biol. Chem.275:15099-15105(2000) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: FUNCTION IN ACTIVATION OF STAT3
    23. 24.
      "Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease."
      Hellawell G.O. , Turner G.D. , Davies D.R. , Poulsom R. , Brewster S.F. , Macaulay V.M.
      Cancer Res.62:2942-2950(2002) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: TISSUE SPECIFICITY
    24. 25.
      "Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved."
      Pandini G. , Frasca F. , Mineo R. , Sciacca L. , Vigneri R. , Belfiore A.
      J. Biol. Chem.277:39684-39695(2002) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: FUNCTION;FORMATION OF A HYBRID RECEPTOR WITH INSR
    25. 26.
      "RACK1, an insulin-like growth factor I (IGF-I) receptor-interacting protein, modulates IGF-I-dependent integrin signaling and promotes cell spreading and contact with extracellular matrix."
      Hermanto U. , Zong C.S. , Li W. , Wang L.H.
      Mol. Cell. Biol.22:2345-2365(2002) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: INTERACTION WITH GNB2L1
    26. 27.
      "Type 1 insulin-like growth factor receptor (IGF-IR) signaling inhibits apoptosis signal-regulating kinase 1 (ASK1)."
      Galvan V. , Logvinova A. , Sperandio S. , Ichijo H. , Bredesen D.E.
      J. Biol. Chem.278:13325-13332(2003) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: FUNCTION;INTERACTION WITH MAP3K5
    27. 28.
      "Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor."
      Girnita L. , Girnita A. , Larsson O.
      Proc. Natl. Acad. Sci. U.S.A.100:8247-8252(2003) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: UBIQUITINATION BY MDM2;INTERACTION WITH MDM2
    28. 29.
      "Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth."
      Girnita A. , Girnita L. , del Prete F. , Bartolazzi A. , Larsson O. , Axelson M.
      Cancer Res.64:236-242(2004) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: ENZYME REGULATION
    29. 30.
      "{beta}-Arrestin is crucial for ubiquitination and down-regulation of the insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase."
      Girnita L. , Shenoy S.K. , Sehat B. , Vasilcanu R. , Girnita A. , Lefkowitz R.J. , Larsson O.
      J. Biol. Chem.280:24412-24419(2005) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: INTERACTION WITH ARRB1 AND ARRB2
    30. 31.
      "JAK/STAT3 pathway is involved in survival of neurons in response to insulin-like growth factor and negatively regulated by suppressor of cytokine signaling-3."
      Yadav A. , Kalita A. , Dhillon S. , Banerjee K.
      J. Biol. Chem.280:31830-31840(2005) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: INTERACTION WITH STAT3
    31. 32.
      "Hybrid receptors formed by insulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity irrespective of the IR splice variant."
      Slaaby R. , Schaeffer L. , Lautrup-Larsen I. , Andersen A.S. , Shaw A.C. , Mathiasen I.S. , Brandt J.
      J. Biol. Chem.281:25869-25874(2006) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: FUNCTION;FORMATION OF A HYBRID RECEPTOR WITH INSR
    32. 33.
      "The insulin-like growth factor 1 (IGF-1) receptor is a substrate for gamma-secretase-mediated intramembrane proteolysis."
      McElroy B. , Powell J.C. , McCarthy J.V.
      Biochem. Biophys. Res. Commun.358:1136-1141(2007) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: SUBCELLULAR LOCATION;PROTEOLYTIC PROCESSING
    33. 34.
      "The insulin-like growth factor 1 receptor in cancer: old focus, new future."
      Hartog H. , Wesseling J. , Boezen H.M. , van der Graaf W.T.
      Eur. J. Cancer43:1895-1904(2007) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: REVIEW ON IGF1R IN CANCER
    34. 35.
      "Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle."
      Daub H. , Olsen J.V. , Bairlein M. , Gnad F. , Oppermann F.S. , Korner R. , Greff Z. , Keri G. , Stemmann O. , Mann M.
      Mol. Cell31:438-448(2008) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
      tissue: Cervix carcinoma.
    35. 36.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
    36. 37.
      "Development and validation of a method for profiling post-translational modification activities using protein microarrays."
      Del Rincon S.V. , Rogers J. , Widschwendter M. , Sun D. , Sieburg H.B. , Spruck C.
      PLoS ONE5:E11332-E11332(2010) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: SUMOYLATION
    37. 38.
      "Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis."
      Olsen J.V. , Vermeulen M. , Santamaria A. , Kumar C. , Miller M.L. , Jensen L.J. , Gnad F. , Cox J. , Jensen T.S. , Nigg E.A. , Brunak S. , Mann M.
      Sci. Signal.3:RA3-RA3(2010) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]
      tissue: Cervix carcinoma.
    38. 39.
      "Polyubiquitination of insulin-like growth factor I receptor (IGF-IR) activation loop promotes antibody-induced receptor internalization and down-regulation."
      Mao Y. , Shang Y. , Pham V.C. , Ernst J.A. , Lill J.R. , Scales S.J. , Zha J.
      J. Biol. Chem.286:41852-41861(2011) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: UBIQUITINATION AT LYS-1168 AND LYS-1171
    39. 40.
      "Crystal structure of the first three domains of the type-1 insulin-like growth factor receptor."
      Garrett T.P. , McKern N.M. , Lou M. , Frenkel M.J. , Bentley J.D. , Lovrecz G.O. , Elleman T.C. , Cosgrove L.J. , Ward C.W.
      Nature394:395-399(1998) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 31-492;DISULFIDE BONDS;GLYCOSYLATION AT ASN-51; ASN-135; ASN-244 AND ASN-314
    40. 41.
      "Structure and autoregulation of the insulin-like growth factor 1 receptor kinase."
      Favelyukis S. , Till J.H. , Hubbard S.R. , Miller W.T.
      Nat. Struct. Biol.8:1058-1063(2001) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 988-1286 IN COMPLEX WITH AMP-PCP AND PEPTIDE SUBSTRATE;CATALYTIC ACTIVITY;ACTIVE SITE;ENZYME REGULATION;IDENTIFICATION BY MASS SPECTROMETRY;PHOSPHORYLATION AT TYR-1161; TYR-1165 AND TYR-1166
    41. 42.
      "Crystal structure of bisphosphorylated IGF-1 receptor kinase: insight into domain movements upon kinase activation."
      Pautsch A. , Zoephel A. , Ahorn H. , Spevak W. , Hauptmann R. , Nar H.
      Structure9:955-965(2001) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 981-1286 IN COMPLEX WITH ANP;AUTOPHOSPHORYLATION;ACTIVE SITE;IDENTIFICATION BY MASS SPECTROMETRY
    42. 43.
      "Crystal structure of the Apo, unactivated insulin-like growth factor-1 receptor kinase. Implication for inhibitor specificity."
      Munshi S. , Kornienko M. , Hall D.L. , Reid J.C. , Waxman L. , Stirdivant S.M. , Darke P.L. , Kuo L.C.
      J. Biol. Chem.277:38797-38802(2002) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 974-1294
    43. 44.
      "Structure of apo, unactivated insulin-like growth factor-1 receptor kinase at 1.5 A resolution."
      Munshi S. , Hall D.L. , Kornienko M. , Darke P.L. , Kuo L.C.
      Acta Crystallogr. D59:1725-1730(2003) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) OF 974-1294
    44. 45.
      "Discovery and initial SAR of 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-ones as inhibitors of insulin-like growth factor 1-receptor (IGF-1R)."
      Velaparthi U. , Wittman M. , Liu P. , Stoffan K. , Zimmermann K. , Sang X. , Carboni J. , Li A. , Attar R. , Gottardis M. , Greer A. , Chang C.Y. , Jacobsen B.L. , Sack J.S. , Sun Y. , Langley D.R. , Balasubramanian B. , Vyas D.
      Bioorg. Med. Chem. Lett.17:2317-2321(2007) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 982-1286 IN COMPLEX WITH BENZIMIDAZOLE PYRIDINONE INHIBITOR;CATALYTIC ACTIVITY;ENZYME REGULATION
    45. 46.
      "Lead identification to generate isoquinolinedione inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment."
      Mayer S.C. , Banker A.L. , Boschelli F. , Di L. , Johnson M. , Kenny C.H. , Krishnamurthy G. , Kutterer K. , Moy F. , Petusky S. , Ravi M. , Tkach D. , Tsou H.R. , Xu W.
      Bioorg. Med. Chem. Lett.18:3641-3645(2008) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 981-1286;PHOSPHORYLATION AT TYR-1161; TYR-1165 AND TYR-1166
    46. 47.
      "Small-molecule inhibition and activation-loop trans-phosphorylation of the IGF1 receptor."
      Wu J. , Li W. , Craddock B.P. , Foreman K.W. , Mulvihill M.J. , Ji Q.S. , Miller W.T. , Hubbard S.R.
      EMBO J.27:1985-1994(2008) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 986-1286 IN COMPLEX WITH INHIBITOR PQIP;SUBUNIT;AUTOPHOSPHORYLATION;CATALYTIC ACTIVITY;ACTIVE SITE;ENZYME REGULATION
    47. 48.
      "Lead identification to generate 3-cyanoquinoline inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment."
      Miller L.M. , Mayer S.C. , Berger D.M. , Boschelli D.H. , Boschelli F. , Di L. , Du X. , Dutia M. , Floyd M.B. , Johnson M. , Kenny C.H. , Krishnamurthy G. , Moy F. , Petusky S. , Tkach D. , Torres N. , Wu B. , Xu W.
      Bioorg. Med. Chem. Lett.19:62-66(2009) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 981-1286 IN COMPLEX WITH 3-CYANOQUINOLINE INHIBITOR;CATALYTIC ACTIVITY;ENZYME REGULATION;PHOSPHORYLATION AT TYR-1161; TYR-1165 AND TYR-1166
    48. 49.
      "Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development."
      Wittman M.D. , Carboni J.M. , Yang Z. , Lee F.Y. , Antman M. , Attar R. , Balimane P. , Chang C. , Chen C. , Discenza L. , Frennesson D. , Gottardis M.M. , Greer A. , Hurlburt W. , Johnson W. , Langley D.R. , Li A. , Li J. , more...
      J. Med. Chem.52:7360-7363(2009) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.08 ANGSTROMS) OF 982-1286 IN COMPLEX WITH BMS-754807;CATALYTIC ACTIVITY;ENZYME REGULATION
    49. 50.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (1.79 ANGSTROMS) OF 983-1286 IN COMPLEX WITH MSC1609119A-1;CATALYTIC ACTIVITY;ENZYME REGULATION
    50. 51.
      "Proline isosteres in a series of 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitors of IGF-1R kinase and IR kinase."
      Sampognaro A.J. , Wittman M.D. , Carboni J.M. , Chang C. , Greer A.F. , Hurlburt W.W. , Sack J.S. , Vyas D.M.
      Bioorg. Med. Chem. Lett.20:5027-5030(2010) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.11 ANGSTROMS) OF 982-1286 IN COMPLEXES WITH INHIBITORS;CATALYTIC ACTIVITY;ENZYME REGULATION
    51. 52.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 951-1286 IN COMPLEX WITH BIS-AZAINDOLE INHIBITOR;AUTOPHOSPHORYLATION;ENZYME REGULATION
    52. 53.
      "Discovery of the first non-ATP competitive IGF-1R kinase inhibitors: advantages in comparison with competitive inhibitors."
      Lesuisse D. , Mauger J. , Nemecek C. , Maignan S. , Boiziau J. , Harlow G. , Hittinger A. , Ruf S. , Strobel H. , Nair A. , Ritter K. , Malleron J.L. , Dagallier A. , El-Ahmad Y. , Guilloteau J.P. , Guizani H. , Bouchard H. , Venot C.
      Bioorg. Med. Chem. Lett.21:2224-2228(2011) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 982-1286 IN COMPLEX WITH HYDANTOIN DERIVATIVE;CATALYTIC ACTIVITY;ENZYME REGULATION
    53. 54.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 988-1286 IN COMPLEX WITH 2,4-BIS-ARYLAMINO-1,3-PYRIMIDINE INHIBITOR;CATALYTIC ACTIVITY;ENZYME REGULATION
    54. 55.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS IGF1RES GLN-138 AND ASN-145;CHARACTERIZATION OF VARIANTS IGF1RES GLN-138 AND ASN-145
    55. 56.
      "Mutation at cleavage site of insulin-like growth factor receptor in a short-stature child born with intrauterine growth retardation."
      Kawashima Y. , Kanzaki S. , Yang F. , Kinoshita T. , Hanaki K. , Nagaishi J. , Ohtsuka Y. , Hisatome I. , Ninomoya H. , Nanba E. , Fukushima T. , Takahashi S.
      J. Clin. Endocrinol. Metab.90:4679-4687(2005) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT IGF1RES GLN-739;CHARACTERIZATION OF VARIANT IGF1RES GLN-739
    Product Feedback Wall
    Hot Genes
    Atf2 ASPRO ACE ALCAM C19orf80 Trap1a Gdf5
    Top Searches
    Ubiquitin-protein ligase metalloproteinase Ubiquitin ELISA Tumor necrosis Alpha Asprosin TRAP1A
    Why choose EIAAB
    Our products have been quoted by many publications in famous journals such as Cell; Cell Metabolism; Hepatology; Biomaterials.more
    Further Information
    About us Protein center Bank account Distributors Terms & Conditions Career eiaab.com.cn

    Copyright & copy www.eiaab.com2006-2016 All Rights Reserved    EIAab         Email:eiaab@eiaab.com

    鄂ICP备10015095号-1

    鄂公网安备 42018502005535号

    Twitter